A compact Cas12f nuclease shows high editing efficiency in human cells, with structural insights enabling an engineered variant potentially suited for future AAV‑compatible delivery.
The company's strong cash position gives investors confidence in the gene-editing stock.
Scientists have taken an important step toward a gene therapy that could one day turn off the extra genetic material that ...
A research team has discovered an enhanced CRISPR gene-editing system that could enable targeted delivery inside the human ...
The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling ...
CRISPR Cas9 gene therapy explained with DNA scissors, hereditary diseases treatment, and designer babies ethical dilemmas ...
The last time The Lancet Microbe featured an Editorial on CRISPR was in November 2020, to mark that year’s Nobel Prize in Chemistry, jointly awarded to Emmanuelle Charpentier and Jennifer A Doudna for ...
The global cell therapy technologies market is set to grow from USD 4.41 billion in 2025 to USD 7.91 billion by 2030, ...
Morning Overview on MSN
AI-guided CRISPR tool aims to make DNA edits more precise and safer
Stanford Medicine researchers have built CRISPR-GPT, a large language model designed to automate the full arc of gene-editing experiments, from selecting the right CRISPR system to designing guide ...
Vertex Pharmaceuticals' (NASDAQ: VRTX) stock price is up, but its Casgevy sales partner, CRISPR Therapeutics (NASDAQ: CRSP), is the real buy for long-term investors. Shares of Vertex, a biotech based ...
CRISPR-based therapy is a transformative approach to medicine that allows for targeted changes to the genome by directly addressing the source of disease, or to the epigenome through silencing of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results